Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012–2013

References

• European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC 2013; doi 10.2900/86011
   Google Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34:1–14.
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:18–55.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Fowler VG. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis. 2013;56:1779–1788.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49:325–327.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755–771.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections. A systematic review and meta-analysis. JAMA. 2014;312:1552–1564.
   PubMed Web of Science ®Google Scholar
• Howden BP, Davies JK, Johnson PDR, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Micro Rev. 2010;23:99–139.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement; CLSI document M100-S24. Wayne, PA: CLSI, 2014.
   Google Scholar
• Wootton M, Howe RA, Hillman R, et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001;47:399–403.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Vidaillac C, Sader HS, et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol. 2013;51:2077–2081.
   PubMed Web of Science ®Google Scholar
• Keel RA, Sutherland CA, Aslanzadeh J, et al. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis. 2010;68:326–329.
   PubMed Web of Science ®Google Scholar
• Gould IM, Cauda R, Esposito S, et al. Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents. 2011;37:202–209.
   PubMed Web of Science ®Google Scholar
• Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536–1542.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Paterson D. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55:405–410.
   PubMed Web of Science ®Google Scholar
• Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol Med Microbiol. 2012;65:158–168.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10–52.
   PubMed Web of Science ®Google Scholar
• Casalta JP, Zaratzian C, Hubert S, et al. Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin—Preliminary report. Int J Antimicrob Agents. 2013;42:190–191.
   PubMed Web of Science ®Google Scholar
• Campbell ML, Marchaim D, Pogue JM, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother. 2012;46:1587–1597.
   PubMed Web of Science ®Google Scholar
• Avery LM, Steed ME, Woodruff AE, et al. Daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 2012;6:5990–5993.
   Web of Science ®Google Scholar
• Harbarth S, von Dach E, Pagani L, et al. Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother. 2015;70:264–272.
   PubMed Web of Science ®Google Scholar
• Plachouras D, Kavatha D, Antoniadou A, et al. Dispensing of antibiotics without prescription in Greece 2008: another link in the antibiotic resistance chain. Euro Surveill. 2010;15:19488.
   PubMedGoogle Scholar
• Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009;9:617–624.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Tsakris A, Sader HS, et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother. 2012;67:1321–1324.
   PubMed Web of Science ®Google Scholar